Doc #123 — Midwifery and Maternity Care Under Isolation

---

RECOMMENDED ACTIONS

Phase 1 — First two weeks [IMMEDIATE to URGENT]

1. Inventory all oxytocin stocks nationally — hospital pharmacies, community midwifery practices, wholesale distributors. Aggregate into a single national count. Oxytocin (Syntocinon) has a shelf life of approximately 2–3 years under refrigeration; stock levels and expiry dates must be known immediately. [Phase: 1 — IMMEDIATE]

2. Inventory all maternity-specific consumables — misoprostol, ergometrine, magnesium sulfate (eclampsia), neonatal resuscitation equipment, infant vitamin K, Rhesus anti-D immunoglobulin, epidural kits, prostaglandins for induction, ultrasound gel. Aggregate with the Doc #116 national pharmaceutical inventory. [Phase: 1 — IMMEDIATE]

3. Issue national guidance to all LMCs and maternity facilities: preserve oxytocin for active management of third stage of labour (AMTSL) in all births; do not use for elective induction or augmentation unless clinical necessity is clear. [Phase: 1 — IMMEDIATE]

4. Suspend elective caesarean sections. Caesarean delivery reserved for clinical indications assessed by senior obstetrician. This preserves surgical consumables (Doc #117) and anaesthetic agents for emergencies. [Phase: 1 — IMMEDIATE]

5. Activate all registered midwives. Contact every midwife with a current Annual Practising Certificate (approximately 3,200–3,400)⁹ — including those not currently practising — and establish a national maternity workforce registry. [Phase: 1 — URGENT]

Phase 1 — First three months [HIGH PRIORITY]

6. Establish national maternity triage protocols. Which births require hospital attendance? Which can safely occur at home or in primary birthing units? Standardise risk assessment criteria and referral pathways. Publish and distribute to all LMCs and hospital maternity units. [Phase: 1]

7. Begin training community birth attendants. Identify candidates from nursing, health science, and community health backgrounds. Develop a condensed training programme (see Section 7) for supervised community birth attendance. Target: first cohort of 200–400 community birth attendants trained within 6 months. [Phase: 1]

8. Redistribute maternity consumables from private hospitals and fertility clinics to the national stock. Private obstetric practices and fertility clinics hold oxytocin, surgical supplies, and ultrasound equipment that must be integrated into national allocation. [Phase: 1]

9. Establish regional birthing centres in areas currently distant from secondary hospital maternity services — particularly rural South Island, East Cape, Northland. Use existing community facilities (primary birthing units, medical centres, marae-based health clinics). [Phase: 1]

10. Begin community education programme on home birth preparation. As hospital births decline, families need practical guidance: what to prepare, what to expect, when to transfer, how to support the midwife. [Phase: 1]

Phase 1–2 — Months 3–18 [PRIORITY]

11. Implement managed transition to community-based birth. As consumables deplete, progressively shift low-risk births out of secondary and tertiary hospitals. Maintain hospital maternity for high-risk pregnancies and emergency access. Target: 50–60% community/home birth rate within 12 months. [Phase: 1–2]

12. Prioritise oxytocin for Doc #119 local production assessment. Oxytocin is a nine-amino-acid peptide. Its synthesis is technically feasible but requires peptide chemistry capability that NZ does not currently have. This must be assessed honestly — see Section 5. [Phase: 1–2]

13. Develop misoprostol rationing protocol. Misoprostol (oral/sublingual) is a partial substitute for oxytocin in PPH prevention and treatment. It is a tablet with a longer shelf life than injectable oxytocin and does not require refrigeration.¹⁰ Allocate misoprostol stocks for use when oxytocin is unavailable. [Phase: 1–2]

14. Establish perinatal mental health support in coordination with Doc #122. Pregnancy and birth under crisis conditions carry significant psychological burden. Community midwives are well-positioned to provide screening and first-line support; specialist referral pathways must remain functional. [Phase: 1–2]

15. Maintain and repair ultrasound equipment. Obstetric ultrasound is NZ’s primary tool for detecting placenta praevia, malpresentation, multiple pregnancy, and fetal abnormalities — conditions that determine whether hospital birth is necessary. Prioritise ultrasound maintenance and spare parts for maternity services. [Phase: 1–2]

Phase 2–3 — Years 1–7 [STRATEGIC]

16. Scale community birth attendant training to replace retiring midwives and meet workforce needs. Target: maintain a ratio of at least one trained birth attendant per 20–25 births per year, or approximately 2,500–3,000 active practitioners nationally. [Phase: 2–3]

17. Develop herbal uterotonic protocols for PPH prevention and management using locally available plant medicines as partial substitutes when pharmaceutical uterotonics are exhausted. See Section 5. [Phase: 2–3]

18. Establish regional surgical maternity hubs — a smaller number of well-resourced hospitals (perhaps 8–12 nationally) maintaining caesarean capability, rather than attempting to sustain surgical obstetrics at all current locations. Concentrate surgical consumables, anaesthetists, and obstetricians at these hubs. [Phase: 2–3]

19. Integrate traditional Māori birthing practices into national maternity framework. Māori birth traditions have direct clinical value, including knowledge of positioning, massage techniques, and whānau-centred support structures — see Sections 2.2, 3.6, and 5.2. [Phase: 2–3]

20. Develop neonatal care protocols for resource-limited settings. Kangaroo mother care for premature infants, simplified resuscitation algorithms, community-based newborn care. See Section 6. [Phase: 2–3]

---

ECONOMIC JUSTIFICATION

Labour requirements

Existing maternity workforce (no new investment required): NZ has approximately 3,200–3,400 midwives with Annual Practising Certificates.¹¹ Approximately 2,800 are active in clinical practice. This is one of the highest midwife-to-population ratios in the world. Additionally, NZ has approximately 200–250 practising obstetricians and a substantial number of general practitioners with maternity experience.¹²

New training investment: Training 200–400 community birth attendants per year requires approximately 10–20 full-time-equivalent midwifery educators and clinical preceptors, plus training facility costs. This is modest relative to the alternative — unattended births.

Comparison with alternatives:

• Do nothing: Without organised maternity care, maternal mortality rises to 500–1,000+ per 100,000 — the historical rate in societies without skilled birth attendance.¹³ At 60,000 births per year, this means 300–600+ maternal deaths annually, compared with approximately 6–9 under the current system. The entire purpose of this document is to prevent this.
• Hospital-only model: Attempting to maintain hospital-based birth for all 60,000 deliveries per year consumes surgical, pharmaceutical, and facility resources at an unsustainable rate. The community-based model described here preserves hospital resources for the 10–15% of births that genuinely need them.

Opportunity cost: The maternity workforce is already trained and practising. The additional training investment (10–20 FTE educators) is negligible against a working-age population of approximately 2.5 million. There is no significant opportunity cost — these practitioners would be doing this work regardless.

---

1. NZ’S MATERNITY SYSTEM: A GENUINE STRUCTURAL ADVANTAGE

1.1 The Lead Maternity Carer model

NZ operates a maternity system unlike most developed countries. Under the Primary Maternity Services Notice, every pregnant woman is entitled to a Lead Maternity Carer (LMC) who provides continuity of care throughout pregnancy, labour, birth, and the postnatal period (up to six weeks).¹⁴ The LMC model was established in 1996 following the Nurses Amendment Act 1990, which restored autonomous practice to NZ midwives — making NZ one of the first countries to formally recognise midwifery as a standalone profession independent of nursing or medical oversight.¹⁵

Approximately 94% of women register with an LMC. Of those, roughly 92% choose a midwife as their LMC; the remainder choose a GP or specialist obstetrician.¹⁶ This means the vast majority of NZ births are already managed by midwives as lead practitioners, with medical specialists available for consultation and referral but not routinely involved in normal birth.

Why this matters for isolation: In most developed countries (the US, Australia, much of Europe), maternity care is physician-led, hospital-centred, and dependent on continuous access to medical technology. Transitioning such systems to community-based care under supply constraints would require a fundamental restructuring of practice, culture, and training. NZ does not face this problem. The NZ system is already designed around midwifery-led, community-based care. The shift toward more home and community births under isolation is a scaling of existing practice, not a departure from it.

1.2 Current birth settings

Under normal conditions, NZ births occur in three settings:¹⁷

• Secondary and tertiary hospitals (specialist obstetric units): approximately 70–75% of births
• Primary birthing units (midwife-led, no surgical or anaesthetic capability on-site): approximately 10–15% of births
• Home births: approximately 3–5% of births

The high hospital rate may appear to contradict the claim that NZ’s system is community-oriented. It does not. Many hospital births in NZ are attended primarily by the community LMC midwife, with hospital facilities used as a precautionary setting rather than because the birth requires hospital-level intervention. The distinction is important: the midwife provides the care; the hospital provides the building. Moving these births to community settings requires changing the location, not the model of care.

1.3 NZ’s midwifery workforce

NZ’s midwifery workforce is regulated by the Midwifery Council of New Zealand (MCNZ). To practise, midwives must hold an Annual Practising Certificate, which requires completion of a four-year Bachelor of Midwifery programme (offered at Otago Polytechnic, ARA Institute of Canterbury, and Waikato Institute of Technology, among others), registration, and ongoing professional development.¹⁸¹⁹

Workforce strengths: - High ratio of midwives to births (approximately 1 practising midwife per 18–22 births per year) - Training includes home birth, primary unit birth, and physiological birth management — not only hospital-based skills - Midwives carry their own caseloads independently; they are accustomed to autonomous decision-making - NZ midwives are trained in neonatal resuscitation, suturing, and emergency management including PPH

Workforce vulnerabilities: - Geographic distribution is uneven — rural and remote areas already face midwife shortages under normal conditions²⁰ - The workforce is aging — a significant proportion of practising midwives are over 50 - Burnout and attrition are ongoing concerns even pre-crisis; on-call demands of caseloading midwifery are high - Māori and Pacific communities are underserved relative to population share²¹ - Under isolation, there is no mechanism to recruit internationally trained midwives — NZ’s workforce is what it has

1.4 Obstetricians and specialist services

NZ has approximately 200–250 practising obstetricians/gynaecologists, concentrated in urban centres (Auckland, Wellington, Christchurch, Hamilton, Dunedin).²² These specialists provide consultation, high-risk pregnancy management, and perform caesarean sections and other operative deliveries (vacuum, forceps). Under isolation, the obstetric workforce is also finite and non-renewable — training a new obstetrician requires approximately 12–14 years of medical and specialist education.

---

2. THE TRANSITION: FROM HOSPITAL TO COMMUNITY

2.1 Why births move out of hospitals

Under normal conditions, the marginal cost of a hospital birth is modest — the facility is there, staffed, supplied. Under isolation, the calculus changes because every hospital birth consumes finite resources:

• Pharmaceutical consumables: oxytocin for AMTSL, IV fluids, antibiotics for GBS prophylaxis, epidural drugs, prostaglandins for induction
• Disposable supplies: sterile gloves, drapes, suture material, catheter kits, IV cannulae
• Electricity and water: reliable for now, but hospital operational costs are non-trivial
• Staff concentration: specialist midwives and obstetricians stationed in hospitals are unavailable for community work

As these consumables deplete (timelines vary — see Doc #116 and Doc #117), hospital birth becomes progressively more resource-intensive relative to community birth. The rational response is to reserve hospital birth for cases that require hospital-level intervention and shift all others to community settings.

2.2 What “community birth” means in practice

Community birth under this framework means birth attended by a trained midwife (or community birth attendant) in a non-hospital setting — the woman’s home, a primary birthing unit, a community health centre, or a marae-based facility. The critical requirements are:

• A skilled attendant trained in normal birth management, neonatal resuscitation, PPH recognition and initial management, and transfer decision-making
• Basic equipment: sterile cord clamp/tie and scissors, clean towels, a means of warming the newborn (skin-to-skin), suction device (bulb syringe), stethoscope or Pinard horn (fetal heart rate monitoring), blood pressure cuff
• A transfer plan: pre-identified route to the nearest facility with surgical capability, transport arranged, communication available (phone or radio)
• Uterotonic agent for AMTSL: oxytocin if available, misoprostol if not, manual techniques if neither

Māori traditional birth practices — upright positioning (kneeling, squatting, supported standing) and mirimiri (abdominal and back massage) — are well-supported by modern evidence as reducing labour duration, instrumental delivery rates, and severe perineal trauma.²³²⁴ These practices align naturally with community-based birth settings where hospital beds are absent. Postpartum uterine massage (mirimiri) also aligns with the manual PPH prevention techniques described in Section 5.2.

The whānau (extended family) model provides practical labour support, postpartum household assistance, and breastfeeding support — reducing demand on the professional maternity workforce and improving outcomes.²⁵ Marae and whānau ora services provide existing community infrastructure for birth support, particularly in rural areas. These facilities and networks should be formally integrated into the national maternity framework — not as a parallel system but as a core component.

NZ’s own maternity outcomes data, reported through the PMMRC and Ministry of Health “Report on Maternity” series, shows that planned home and primary unit births attended by LMC midwives have comparable outcomes for low-risk women.²⁶ This is consistent with international evidence, including the Birthplace in England study, which found that planned home birth attended by a skilled midwife for low-risk multiparous women has equivalent or lower rates of intervention and adverse outcome compared with hospital birth. For nulliparous women (first births), the evidence shows slightly higher rates of transfer to hospital, which is why access to transfer capability matters.

2.3 Risk stratification

Not all births can safely occur in the community. A national risk stratification protocol must identify which pregnancies require hospital-level care. High-risk indications for hospital birth include:²⁷

• Previous caesarean section (risk of uterine rupture in labour — approximately 0.5% for one prior caesarean, higher for multiple)²⁸
• Placenta praevia (detected by ultrasound — mandates caesarean delivery)
• Pre-eclampsia / eclampsia (requires magnesium sulfate, antihypertensive drugs, and rapid access to emergency caesarean)
• Multiple pregnancy (twins, triplets — higher complication rates)
• Breech presentation not resolved by external cephalic version (some breech births can be safely attended by experienced practitioners, but this requires specific skill)
• Preterm labour (before 37 weeks — particularly before 34 weeks where neonatal care is critical)
• Significant maternal medical conditions (cardiac disease, severe anaemia, uncontrolled diabetes, HIV)
• Known fetal anomalies requiring immediate neonatal intervention

Under the current system, the threshold for hospital referral is low — when in doubt, transfer. Under isolation, the threshold will need to rise as hospital capacity is reserved for higher-risk cases. This is a clinical judgment with real consequences: every unnecessary hospital birth consumes finite resources; every community birth that should have been in hospital risks a preventable death. The risk stratification protocol must be clear, evidence-based, and regularly updated as resource availability changes.

2.4 Timeline for transition

The transition is not sudden. It is driven by consumable depletion rates:

• Phase 1 (Months 0–12): Hospital birth still available for all who choose it, but elective interventions restricted. Begin encouraging community birth for low-risk women. Target: 30–40% community birth rate.
• Phase 2 (Years 1–3): Pharmaceutical and consumable rationing bites. Epidural anaesthesia unavailable for most births. Hospital birth reserved for identified risk factors. Target: 50–60% community birth rate.
• Phase 3 (Years 3–7): Hospital maternity concentrated at regional hubs with maintained surgical capability. Community birth is the default for all low-risk pregnancies. Target: 70–80% community birth rate.
• Phase 4 (Years 7–15): Steady state. Hospital surgical obstetric capability maintained at 8–12 centres nationally using locally produced and reusable supplies (Doc #117). Community birth with trained attendants is the norm.

---

3. CRITICAL CONSUMABLES AND THEIR DEPLETION

3.1 Oxytocin (Syntocinon)

What it does: Oxytocin is a synthetic peptide hormone used in two ways in maternity care: (a) to induce or augment labour (by intravenous infusion), and (b) to prevent and treat postpartum haemorrhage (by intramuscular injection as part of active management of the third stage of labour — AMTSL).²⁹

Why it matters: AMTSL with oxytocin reduces the incidence of PPH (blood loss >500 mL) by approximately 50–60% compared with physiological management of the third stage.³⁰ PPH is the leading cause of maternal death worldwide and remains a significant cause of severe maternal morbidity even in well-resourced settings. Without oxytocin, NZ’s PPH rate will increase substantially.

Stock and depletion: NZ uses approximately 60,000–80,000 ampoules of oxytocin per year for maternity indications (estimate based on birth numbers and usage patterns — exact figure requires verification from Te Whatu Ora procurement data).³¹ Wholesale stock at any given time is typically 3–6 months of supply. Syntocinon ampoules have a shelf life of 2–3 years refrigerated. Under strict rationing (AMTSL use only, no elective induction or augmentation), stocks could be extended to perhaps 2–4 years.

Rationing priority: Oxytocin should be reserved exclusively for PPH prevention and treatment. Use for induction and augmentation of labour should cease except in genuinely life-threatening situations (e.g., pre-eclampsia requiring urgent delivery). This is a clinically defensible decision, though implementation requires clear communication and updated protocols across all DHBs and LMC practices — changing established prescribing habits under crisis conditions involves institutional coordination beyond issuing guidance.

Can NZ produce oxytocin? Oxytocin is a nonapeptide (nine amino acids: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, with a disulfide bridge).³² It was first synthesised by Vincent du Vigneaud in 1953. Solid-phase peptide synthesis is technically feasible but requires specialised reagents (Fmoc-protected amino acids, coupling reagents, resins) that NZ does not produce and would need to develop or import. The honest assessment (see Doc #119) is that domestic oxytocin synthesis is Feasibility [C] — achievable in principle but requiring precursor chemical industries that do not exist. This is a years-to-decades timeline. Oxytocin should be a high priority for early trade with any partner that develops peptide synthesis capability.

3.2 Misoprostol

What it does: Misoprostol is a prostaglandin E₁ analogue used for PPH prevention and treatment (when oxytocin is unavailable), induction of labour, and treatment of incomplete miscarriage.³³

Why it matters as a substitute: Misoprostol is less effective than oxytocin for PPH prevention (reduces PPH by approximately 25–45% vs. 50–60% for oxytocin)³⁴ but has two critical advantages: it is an oral tablet (no injection required), and it is stable at room temperature with a long shelf life (up to 2–3 years). This makes it far more suitable for community-based care than injectable oxytocin, which requires cold chain storage and injection technique.

Stock: NZ holds misoprostol stocks for both maternity and gastric indications. These stocks should be reserved primarily for maternity use once oxytocin depletion approaches. Exact stock levels require inventory.

3.3 Ergometrine

What it does: Ergometrine (ergonovine) is a uterotonic derived from ergot alkaloids. It was the standard PPH treatment before synthetic oxytocin became available.³⁵

Limitations: Ergometrine causes hypertension and is contraindicated in pre-eclampsia and cardiac disease. It requires refrigeration and has a shorter shelf life than oxytocin. It also causes nausea and vomiting at therapeutic doses. Despite these limitations, it is a functional uterotonic and was used for decades as the primary PPH treatment.

Stock: NZ holds some ergometrine stocks. These should be preserved and allocated alongside oxytocin under the national pharmaceutical triage (Doc #116).

3.4 Magnesium sulfate

What it does: Magnesium sulfate is the standard treatment for eclampsia (seizures associated with pre-eclampsia) and is used for seizure prevention in severe pre-eclampsia. It is also used as a neuroprotectant for premature infants.³⁶

Why it matters: Pre-eclampsia/eclampsia affects approximately 2–5% of pregnancies and is a leading cause of maternal and perinatal death worldwide.³⁷ Without magnesium sulfate, eclampsia management reverts to less effective anticonvulsants (diazepam, phenytoin). Eclampsia-related maternal mortality would increase.

Stock and production potential: Magnesium sulfate is a simple inorganic salt. NZ has magnesium-containing minerals (dolomite, magnesite) and sulfuric acid is a priority for domestic production (Doc #119 dependency on Doc #113). Pharmaceutical-grade magnesium sulfate production is Feasibility [B] — achievable within 2–5 years with dedicated effort.

3.5 Antibiotics

Maternity-specific uses: Group B Streptococcus (GBS) prophylaxis in labour (intravenous penicillin or ampicillin, given to approximately 20–25% of women), treatment of postpartum endometritis, treatment of mastitis, prophylactic antibiotics for caesarean section.³⁸

Depletion impact: As antibiotic stocks deplete (Doc #116), GBS prophylaxis will be curtailed — increasing neonatal GBS sepsis, which has a case fatality rate of approximately 5–10% in term neonates and higher in preterm infants.³⁹ Caesarean section without prophylactic antibiotics increases surgical site infection rates from approximately 3–5% to 10–15%.⁴⁰

Partial mitigation: Crude penicillin is among the early domestic production targets (Doc #119, Tier 2). Sulfonamide antibiotics may also be producible. Neither will match the purity, dosing precision, or spectrum of imported antibiotics — early domestic penicillin will likely have variable potency (perhaps 50–80% of target dose consistency), a narrower spectrum than modern broad-spectrum agents, and higher rates of allergic reaction due to impurities. Despite these gaps, crude penicillin substantially reduces infection-related mortality compared with no antibiotic treatment at all — historically, even impure early penicillin reduced surgical infection mortality by 50–80%.⁴¹

3.6 Suture material

Maternity uses: Repair of perineal tears (first- and second-degree tears occur in approximately 40–60% of vaginal births; third- and fourth-degree tears in 3–5%), repair of episiotomy, uterine closure in caesarean section.⁴²

Substitution: Catgut sutures from sheep intestine are the historical standard and are a near-term local production target (Doc #117). Production requires: sheep intestine (abundant — NZ has approximately 25 million sheep), splitting and scraping of the submucosal layer, chromic acid treatment for “chromic catgut” (slower absorption — requires chromium salts, which NZ does not produce domestically but may source from tanning industry stocks), twisting to desired gauge, sterilisation, and quality-controlled packaging. Feasibility [A/B] for plain catgut, [B] for chromic catgut. Catgut is absorbable and adequate for perineal repair and uterine closure, though it has higher tissue reactivity than synthetic absorbable sutures (Vicryl, Monocryl) — expect approximately 2–3 times greater local inflammatory response, which may increase wound discomfort and modestly increase superficial infection risk. Silk sutures are also locally producible and adequate for skin closure. The performance gap is real but manageable — surgical repair of birth injuries was performed with catgut for the better part of a century.

Local wound care resources: Kawakawa (Piper excelsum) has confirmed anti-inflammatory and mild analgesic properties⁴³ and is potentially useful for perineal wound care. Mānuka honey has well-documented antibacterial properties and is a genuine local resource for wound management, including perineal and caesarean wound care.⁴⁴ Harakeke (Phormium tenax) gel from the leaf base has demonstrated antimicrobial properties and is potentially useful for wound dressings (see also Doc #100 for harakeke fibre processing).⁴⁵⁴⁶

3.7 Other maternity consumables

• Vitamin K: Neonatal vitamin K injection prevents haemorrhagic disease of the newborn (VKDB). Stocks will deplete. Oral vitamin K is a partial alternative but has a measurable efficacy gap: intramuscular vitamin K reduces late-onset VKDB to near zero (approximately 0–0.2 per 100,000), while multiple-dose oral regimens reduce it to approximately 1–2 per 100,000 — a 5–10 fold higher rate, though still far better than no prophylaxis (approximately 4–10 per 100,000 without any vitamin K).⁴⁷ Dietary sources (green vegetables, liver) provide some maternal and neonatal supplementation but are insufficient to prevent VKDB reliably in neonates. This is a real gap.
• Rhesus anti-D immunoglobulin: Given to Rh-negative women to prevent Rh isoimmunisation. This is a blood product that cannot be locally produced. Approximately 10–15% of NZ women are Rh-negative (approximately 15% among NZ European, lower among Maori and Pacific populations).⁴⁸ When anti-D stocks are exhausted, approximately 16% of Rh-negative women carrying Rh-positive babies will develop antibodies per affected pregnancy. In subsequent Rh-incompatible pregnancies, this causes haemolytic disease of the newborn, which ranges from mild anaemia to fatal hydrops fetalis. No local substitute exists.
• Ultrasound gel: Medical ultrasound coupling gel is a water-based polymer gel (typically carbomer or polyacrylic acid based). A functional substitute can be produced locally using carboxymethylcellulose (derivable from wood pulp cellulose, requiring chloroacetic acid and sodium hydroxide) or from natural gums (agar, locust bean gum) thickened in water.⁴⁹ Locally produced gels may have inferior acoustic coupling compared with commercial formulations, potentially reducing image quality at depth — adequate for most obstetric scanning but a measurable performance gap for detailed fetal anomaly assessment. Feasibility [A/B]. Ultrasound machines themselves require maintenance and will eventually fail — see Section 3.8.
• IV fluids and cannulae: Normal saline and Hartmann’s solution production is Feasibility [A/B] (Doc #119). Reusable glass bottles and metal needles are producible locally. Single-use plastic IV sets will deplete.

3.8 Ultrasound equipment

Obstetric ultrasound is NZ’s primary prenatal screening tool. It detects placenta praevia, malpresentation, multiple pregnancy, major fetal anomalies, and ectopic pregnancy. These diagnoses directly determine whether a birth requires surgical capability.⁵⁰

Degradation timeline: Ultrasound machines are electronic equipment with finite component lifespans. Probes degrade with use (crystal element failure, cable damage). Machines depend on software, displays, and power supplies that will eventually fail without replacement parts. Estimated functional life under maintenance: 5–15 years depending on machine age and condition, assuming competent biomedical engineering support.⁵¹

Mitigation: Concentrate ultrasound capability at regional maternity hubs. Train practitioners in clinical assessment techniques that partially substitute for ultrasound (Leopold’s manoeuvres for presentation, fundal height for growth assessment, Pinard horn for fetal heart rate). These clinical skills were the standard of care before ultrasound and remain adequate for most routine assessments, though they miss conditions (placenta praevia, some fetal anomalies) that ultrasound detects.

---

4. CAESAREAN SECTION: WHAT RATE IS NECESSARY?

4.1 Current NZ caesarean rate

NZ’s caesarean section rate was approximately 27–28% in recent years — meaning roughly 16,000–17,000 caesareans per year out of approximately 60,000 births.⁵² This rate has risen steadily over decades and is consistent with international trends in high-income countries.

4.2 What drives the current rate

Not all caesareans are for the same clinical indications. A rough categorisation:⁵³

• Category 1 — Immediate threat to life of mother or baby (cord prolapse, major placental abruption, uterine rupture): approximately 2–3% of births. These are non-discretionary — without surgery, the mother, the baby, or both die.
• Category 2 — Urgent but not immediately life-threatening (fetal distress, failure to progress in advanced labour with clinical concern): approximately 5–8% of births. Clinical judgment determines whether surgery is needed; in many cases, the alternative (continued labour, instrumental delivery) is viable but carries higher risk.
• Category 3 — Elective/planned for medical reasons (repeat caesarean, breech presentation, placenta praevia, maternal medical conditions): approximately 8–10% of births. Some of these are genuinely necessary (placenta praevia mandates caesarean); others reflect a choice between vaginal birth and surgery where both are medically viable (e.g., vaginal birth after caesarean, breech vaginal delivery).
• Category 4 — Maternal request without strict medical indication: a proportion of elective caesareans, difficult to quantify precisely.

4.3 The minimum necessary rate

The WHO has estimated that caesarean rates below 10% are associated with increased maternal and neonatal mortality, while rates above 15% show no additional benefit at the population level.⁵⁴ This suggests that the minimum necessary rate for saving lives is approximately 5–10%, with the range reflecting uncertainty about which marginal caesareans (between 5% and 10%) produce net benefit.

Under isolation, the realistic target is to maintain caesarean capability for Category 1 and the clearest Category 2 indications — approximately 5–8% of births, or 3,000–5,000 caesareans per year. This means approximately 11,000–13,000 fewer caesareans per year than current practice.

4.4 What happens to the women who would have had caesareans

This is the hard question. For women whose current caesarean indication is a Category 1 emergency, there is no alternative — without surgery, they die or their baby dies. Maintaining surgical capability for these cases is non-negotiable.

For women in Category 3 — repeat caesarean, breech presentation — the evidence supports vaginal birth as a viable alternative in most cases, provided skilled attendants are available. Vaginal birth after caesarean (VBAC) has a success rate of approximately 60–80% when properly selected and managed, with a uterine rupture risk of approximately 0.5%.⁵⁵ Breech vaginal birth, largely abandoned in many countries after the Term Breech Trial (2000), was historically normal and remains safe when attended by practitioners trained in breech delivery — a skill that NZ will need to restore and maintain.⁵⁶

For women in Category 2 — fetal distress, failure to progress — the clinical picture is more complex. Some of these births would proceed safely without surgery; some would not. Without continuous electronic fetal monitoring (which will eventually fail), assessment of fetal distress relies on intermittent auscultation (Pinard horn or handheld Doppler), which is less sensitive. Some fetal deaths that would currently be prevented by emergency caesarean will not be prevented. The transition is driven by resource constraints that are unavoidable.

4.5 Maintaining surgical capability

Maintaining even 5–8% caesarean capability for 60,000 births (3,000–5,000 operations per year) requires:⁵⁷

• Anaesthesia: Spinal anaesthesia is the most consumable-efficient technique for caesarean section (single injection, no volatile agent). Spinal needles are reusable if properly sterilised. The limiting consumable is the local anaesthetic agent (bupivacaine or lignocaine) — stocks can be extended by years through careful rationing, and local anaesthetic synthesis is a medium-term production target (Doc #119, Tier 2).
• Sutures: Catgut and silk (locally producible — Doc #117) are adequate for caesarean uterine closure and skin closure.
• Sterile environment: Autoclaves for instrument sterilisation, cloth drapes, ethanol-based antisepsis — all achievable with local production (Doc #117).
• Blood transfusion capability: Caesarean section carries haemorrhage risk. Blood banking using locally produced anticoagulant solutions (citrate-based) is Feasibility [B]. Cross-matching requires reagents that will deplete but can potentially be produced from local blood donors.
• Surgical instruments: Reusable steel instruments last decades with proper maintenance and sharpening.

The conclusion: caesarean capability at a reduced rate (5–8%) is sustainable indefinitely using locally produced consumables. The transition is challenging but achievable, and Doc #117 describes it in detail. Concentrating this capability at 8–12 regional hubs is more efficient than maintaining it at all current sites.

---

5. POSTPARTUM HAEMORRHAGE: THE CENTRAL CHALLENGE

5.1 Why PPH is the defining risk

PPH (blood loss >500 mL after vaginal birth, >1,000 mL after caesarean) occurs in approximately 5–10% of births under current NZ conditions with AMTSL.⁵⁸ Without AMTSL, the rate approximately doubles.⁵⁹ Severe PPH (>1,000 mL) occurs in approximately 1–3% of births and is the condition most likely to cause maternal death.

The sequence of events in uncontrolled PPH is rapid: the uterus fails to contract adequately after placental delivery, blood loss accelerates, hypovolaemic shock develops, and without intervention the woman dies — sometimes within 30–60 minutes of delivery. This is why oxytocin matters so much: it causes the uterus to contract, compressing the blood vessels at the placental site and stopping the bleeding before it becomes life-threatening.

5.2 Management without pharmaceutical uterotonics

When oxytocin, ergometrine, and misoprostol are all unavailable, PPH management relies on mechanical and manual techniques that were the standard of care before the mid-20th century:⁶⁰

1. Uterine massage: Vigorous fundal massage stimulates uterine contraction. This is the first intervention and is often effective for mild PPH.
2. Bimanual compression: One hand is placed inside the uterus (internal hand compresses the fundus against the external hand on the abdomen). This is an emergency technique for severe PPH and is taught to all NZ midwives.
3. Aortic compression: External compression of the abdominal aorta reduces blood flow to the uterus. A temporising measure while preparing for further intervention.
4. Uterine tamponade: A condom catheter or purpose-made balloon inflated within the uterus applies direct pressure to the bleeding site. Condom catheters can be assembled from a latex condom tied over a Foley catheter and inflated with 300–500 mL of saline — requiring latex condoms (imported, finite stock; later potentially replaceable with lamb caecum membranes from NZ’s sheep flock), Foley catheters (reusable if sterilised), and sterile saline (locally producible — Doc #119).⁶¹
5. Controlled cord traction and early breastfeeding: Early nipple stimulation promotes endogenous oxytocin release. Controlled cord traction facilitates complete placental delivery, reducing retained placenta as a cause of PPH. The Māori practice of retaining and carefully examining the placenta (whenua) is clinically compatible with PPH prevention — ensuring complete placental delivery is essential, and the cultural emphasis on placental examination reinforces good clinical practice.
6. Surgical intervention (for uncontrolled PPH): uterine compression sutures (B-Lynch suture), uterine artery ligation, or hysterectomy as a last resort. These require surgical access — one of the reasons surgical maternity hubs must be maintained.

5.3 Herbal uterotonics: honest assessment

Several plant-based medicines have traditional use as uterotonics. The evidence base for their efficacy in PPH prevention is limited but not absent:

• Shepherd’s purse (Capsella bursa-pastoris): Widely used in European and Chinese herbal medicine as a uterotonic. Some laboratory evidence of uterine-stimulating properties. Grows readily in NZ (it is a common weed). Not well-studied in clinical trials for PPH.⁶²
• Raspberry leaf (Rubus idaeus): Traditional use in late pregnancy to “prepare” the uterus. Limited evidence of uterotonic effect. Grows widely in NZ.
• Harakeke (Phormium tenax / P. cookianum): Used in rongoā Māori. Specific uterotonic properties have not been systematically studied in Western scientific literature, but traditional use includes postpartum applications. See also Section 3.6 for wound care applications.

Honest assessment: No herbal preparation has demonstrated efficacy comparable to pharmaceutical oxytocin in controlled trials. The magnitude of the effect, if any, is unknown. These preparations may provide some benefit — or may provide none. They should be investigated systematically (university pharmacology departments at Auckland, Otago, and Canterbury can conduct basic uterine smooth muscle assays on plant extracts) but should not be relied upon as a primary PPH intervention. Feasibility of herbal uterotonics as a clinically validated PPH intervention: [C] — the plants are available, but establishing dosing, efficacy, and safety requires years of pharmacological investigation that has not yet been done. Misleading claims about herbal substitutes for oxytocin would put women’s lives at risk.

5.4 Maternal mortality projections

Current NZ maternal mortality: approximately 10–15 per 100,000 births (varying by year and by definition used — the Perinatal and Maternal Mortality Review Committee reports approximately 10–20 maternal deaths per year from all causes).⁶³

Projected mortality under isolation: This depends critically on the phase and on which consumables remain available.

• Phase 1 (oxytocin available, hospitals functional): Modest increase, perhaps 15–25 per 100,000, primarily from reduction in elective caesarean access and constrained management of complications.
• Phase 2 (oxytocin depleting, community birth dominant): Significant increase, perhaps 40–80 per 100,000, driven primarily by PPH without pharmaceutical uterotonics and by reduced access to emergency caesarean.
• Phase 3+ (steady state, manual techniques established, surgical hubs maintained): Perhaps 50–100 per 100,000 as workforce skill in manual PPH management improves but pharmaceutical substitution remains unavailable.

For context: A maternal mortality ratio of 50–100 per 100,000 is comparable to well-functioning low-income countries with skilled midwifery workforces but limited access to emergency obstetric care — for example, parts of Southeast Asia and North Africa in the early 2000s.⁶⁴ It is approximately 5–10 times NZ’s current rate. It represents an additional 25–50 maternal deaths per year — each one a tragedy, and each one an argument for prioritising oxytocin production and caesarean capability preservation.

This is not inevitable. If NZ can produce or import oxytocin and maintain surgical obstetric capability at regional hubs, maternal mortality could remain below 30 per 100,000 — still elevated, but dramatically better than the no-intervention scenario.

---

6. NEONATAL CARE UNDER RESOURCE CONSTRAINTS

6.1 Current neonatal mortality

NZ’s neonatal mortality rate (deaths in the first 28 days of life) is approximately 2.7–3.2 per 1,000 live births.⁶⁵ Approximately 8–10% of NZ newborns are admitted to neonatal units, and approximately 1.5–2% require intensive care (NICU).⁶⁶

6.2 NICU capability degradation

Modern neonatal intensive care depends on:

• Ventilators and CPAP machines: Electronic devices with disposable circuits. Circuits can be resterilised (Doc #117) but machines will eventually fail.
• Surfactant: Exogenous surfactant for respiratory distress syndrome in premature infants. Entirely imported, no local production feasible. When exhausted, pre-surfactant era mortality rates for very premature infants return — approximately 40–60% mortality for infants born before 28 weeks (depending on gestational age and birth weight), compared with approximately 10–15% with modern care including surfactant.⁶⁷
• Parenteral nutrition: IV amino acids, lipids, and dextrose for infants too immature to feed. Depends on imported sterile solutions.
• Phototherapy equipment: For neonatal jaundice. Phototherapy uses blue light (wavelength approximately 460–490 nm), not ultraviolet.⁶⁸ Blue-spectrum light sources are maintainable using locally available components (fluorescent tubes with appropriate phosphors, blue LED arrays) as long as electrical supply continues, though replacement phosphor-matched tubes will eventually require local manufacturing or trade.
• Incubators: Temperature control for premature infants. Can be improvised from insulated boxes with warming elements as long as electricity is available. Kangaroo mother care (continuous skin-to-skin contact) is an effective alternative for stable premature infants from approximately 28–30 weeks gestation.⁶⁹

6.3 Realistic neonatal care trajectory

• Phase 1: Full NICU capability maintained with existing equipment and consumables.
• Phase 2: Surfactant stocks depleted. CPAP and basic ventilation still available. Mortality increases for very premature infants (<30 weeks). Kangaroo mother care scaled up for stable premature infants.
• Phase 3–4: Ventilator capability degrades as machines fail. NICU capability effectively reverts to temperature management, feeding support, phototherapy, and basic respiratory support (oxygen, improvised CPAP). Neonatal mortality for premature infants returns to approximately pre-1990 levels.⁷⁰

6.4 The viability threshold

Under current NZ practice, resuscitation is generally offered from approximately 23–24 weeks gestation. As NICU capability degrades, the practical viability threshold rises. Without surfactant and mechanical ventilation, survival below approximately 30–32 weeks becomes unlikely.⁷¹ This is a painful reality that must be communicated honestly to parents and clinicians. The alternative — attempting resuscitation without the resources to provide ongoing support — causes suffering without benefit.

Ethical note: Decisions about viability thresholds are among the most difficult in medicine. Under resource constraints, the threshold must be guided by the realistic probability of survival with the care that is actually available — not with the care that would be available in a fully resourced NICU. This means some infants who would survive with modern care will not survive under isolation. Palliative care, family support, and honest communication are essential (Doc #122).

6.5 Kangaroo mother care

Kangaroo mother care (KMC) — continuous skin-to-skin contact between mother and infant, exclusive breastfeeding, early discharge with follow-up — is one of the most evidence-based interventions in neonatal medicine. For stable premature infants from approximately 28 weeks and above, KMC produces outcomes comparable to incubator care and is superior in many low-resource settings.⁷² NZ should scale KMC training and implementation immediately. It is effective, requires no consumables, strengthens bonding, and supports breastfeeding — which becomes even more important when formula milk is unavailable.

---

7. TRAINING AND WORKFORCE EXPANSION

7.1 The workforce gap

NZ’s approximately 2,800 active midwives provide excellent coverage under current conditions. Under isolation, several factors create a workforce gap:

• Attrition without replacement: International recruitment ceases. Domestic training continues but at the pace of the four-year Bachelor of Midwifery programme. Retirements, deaths, and burnout reduce the active workforce each year.
• Geographic redistribution needed: The current workforce is concentrated in urban centres. Community-based care requires practitioners in every community with birthing women — including rural areas that are currently underserved.
• Increased demand: If contraceptive supplies deplete (see Section 8), birth numbers may rise from 60,000 to perhaps 70,000–80,000 per year.

7.2 Community birth attendant training

The core proposal is a condensed training programme for community birth attendants (CBAs) — not full midwives, but skilled attendants trained in normal birth, neonatal resuscitation, PPH recognition and initial management, and transfer decision-making. This follows the model used successfully in many countries and endorsed by the WHO.⁷³

Training structure:

• Duration: 6–12 months (accelerated compared to the four-year midwifery degree, but focused on core competency)
• Prerequisites: Health science background preferred (nursing, paramedic, health science degree) but not mandatory — aptitude, commitment, and community standing are equally important
• Core curriculum:
  • Anatomy and physiology of pregnancy, labour, and birth
  • Antenatal assessment (fundal height, fetal heart rate, blood pressure, urinalysis)
  • Normal labour management (assessment of progress, supportive care, monitoring)
  • Neonatal resuscitation (basic — bag and mask, stimulation, warmth)
  • Active management of the third stage of labour (manual techniques when pharmaceutical uterotonics unavailable)
  • PPH recognition and initial management (uterine massage, bimanual compression, tamponade)
  • Transfer decision-making and communication
  • Breastfeeding support
  • Perineal assessment and basic repair (first- and second-degree tears)
  • Newborn assessment and care
  • Record-keeping
• Clinical requirement: Minimum 30–50 supervised births before independent practice
• Supervision: CBAs practise under the oversight of registered midwives, who provide ongoing mentorship and clinical review

Training capacity: NZ’s existing midwifery education institutions (Otago Polytechnic, ARA, Wintec) can provide the academic framework. Clinical precepting is the bottleneck — each CBA trainee needs supervised clinical experience with births, which means the training programme scales with the number of available preceptors. A realistic first-year output is 200–400 CBAs. Feasibility of CBA training programme: [A] — the training infrastructure, educator workforce, and clinical placement capacity all exist within NZ’s current system; the programme requires coordination and curriculum development, not new capability.

7.3 Maintaining midwifery education

The four-year Bachelor of Midwifery programme should continue — it produces fully qualified midwives capable of managing complex cases, consulting with obstetricians, and training CBAs in turn. Under isolation, the programme may need to adjust its clinical placement model (more community placements, less hospital-based), but its academic standards should not be reduced. NZ’s long-term maternity capability depends on maintaining a core of highly qualified midwifery practitioners.

7.4 Obstetric skills preservation

Certain skills that are currently rare in NZ maternity practice will need to be restored and expanded:

• Breech vaginal birth: Largely replaced by elective caesarean in NZ. Training must be reinstated — experienced practitioners who retain this skill should be identified and assigned as trainers.⁷⁴
• Operative vaginal delivery (vacuum, forceps): An alternative to caesarean section for some complicated births. Forceps delivery is a declining skill internationally and in NZ — vacuum extraction has largely replaced forceps in NZ practice, and training opportunities in forceps delivery have reduced accordingly.⁷⁵ Both skills must be preserved and expanded.
• Symphysiotomy: A surgical widening of the pubic symphysis that allows vaginal delivery in some cases of obstructed labour where caesarean section is unavailable. This procedure has been abandoned in high-resource settings but remains a life-saving option in settings without surgical access. It carries risks (urinary incontinence, chronic pelvic pain) but is preferable to maternal death from obstructed labour.⁷⁶ Training and decision protocols should be developed — reluctantly, but honestly.

---

8. CONTRACEPTION AND FAMILY PLANNING

This section is brief because the topic warrants a dedicated document (see cross-reference to Doc #42 when available).

8.1 Contraceptive supply depletion

NZ’s contraceptive supplies are entirely imported. The most commonly used methods — oral contraceptive pills, injectable medroxyprogesterone acetate (Depo-Provera), subdermal implants (Jadelle), and copper/hormonal IUDs — will deplete on varying timelines:⁷⁷

• Oral contraceptive pills: Shelf life 2–5 years. Stock extends further under SLEP-based extension (Doc #116). Likely available for 3–6 years.
• Jadelle implants: Last 5 years in situ. Women with existing implants have contraception for the remaining life of the device. New insertions draw down stock.
• IUDs (copper): Last 5–10 years in situ. Copper IUDs are the most important long-acting method because they are non-hormonal and have the longest effective life. Priority should be given to copper IUD insertion for women who want long-acting contraception.
• Condoms: Latex condoms degrade over time (shelf life approximately 5 years). Domestic production requires latex (NZ does not produce natural rubber) or animal membrane (lamb cecum — the historical alternative, producible from NZ’s sheep flock).

8.2 Implications for birth rate

As contraceptive supplies deplete, unintended pregnancy rates will increase unless alternative methods are adopted. Fertility awareness methods (calendar, basal body temperature, cervical mucus monitoring) are effective when practised correctly (typical-use failure rate approximately 12–24% per year based on US data, compared with <1% for IUDs and implants — NZ-specific typical-use data is limited, but failure rates are likely comparable).⁷⁸ Community education on fertility awareness should begin early, while pharmaceutical contraception is still available, so that skills are established before they are relied upon.

A gradual increase in the birth rate from approximately 60,000 to 70,000–80,000 per year is plausible over 5–10 years if contraceptive access declines substantially. This has workforce, food, and resource implications across the recovery programme.

---

CRITICAL UNCERTAINTIES

1. Oxytocin stock levels and depletion rate. The single most important data point for maternity planning. Without a precise national inventory, all PPH mortality projections are estimates. Action: complete inventory immediately.

2. Can NZ produce oxytocin domestically? The honest assessment is that this is uncertain and probably years away (Feasibility [C] per Doc #119). Peptide synthesis requires reagents and expertise that NZ does not currently have. This question should be referred to the University of Auckland and University of Otago chemistry departments for urgent feasibility assessment.

3. Workforce attrition rate. How fast does the midwifery workforce shrink through retirement, death, and burnout under crisis conditions? The answer determines how quickly CBA training must scale.

4. Birth rate trajectory. Does the birth rate increase, decrease, or remain stable? Psychological trauma may reduce fertility intentions in the short term; contraceptive depletion increases unintended pregnancy in the medium term. The net effect is uncertain.

5. Cold chain reliability. Oxytocin requires refrigeration. If cold chain fails at storage facilities, remaining stocks degrade more rapidly. Grid reliability (the baseline assumption) is essential.

6. Maternal acceptance of community birth. NZ women are accustomed to choosing their birth setting. Government direction toward community birth will meet resistance from some women, particularly those with previous complicated births. Communication must be honest and empathetic, not authoritarian.

7. Ultrasound equipment longevity. How long can NZ maintain obstetric ultrasound capability? This determines how long clinicians can reliably identify placenta praevia and other conditions requiring surgical delivery. Without ultrasound, some life-threatening conditions will be diagnosed late — or not at all.

8. Caesarean rate floor. The estimate of 5–10% as the minimum necessary rate is drawn from WHO population-level data. The actual minimum for NZ’s specific population (with its demographics, obesity rates, and prior caesarean history) may differ. A woman with two prior caesareans faces a higher uterine rupture risk in vaginal birth than a woman with none — and NZ has a substantial population of women with prior caesarean history.

---

CROSS-REFERENCES

Document	Relevance
Doc #4 — Pharmaceutical and Medical Supply Management	Logistics framework for controlled distribution of all medical supplies including maternity consumables
Doc #116 — Pharmaceutical Rationing and Shelf-Life Extension	Oxytocin rationing, SLEP-based shelf-life extension for maternity drugs, national pharmaceutical triage
Doc #117 — Surgical Consumable Conservation and Local Production	Suture production (catgut, silk), sterilisation, surgical environment maintenance — essential for caesarean capability
Doc #119 — Local Pharmaceutical Production	Assessment of domestic oxytocin, misoprostol, magnesium sulfate, and antibiotic production feasibility
Doc #122 — Mental Health: National Grief and Social Purpose	Perinatal mental health, grief processing for pregnancy loss and neonatal death under isolation
Doc #42 — Contraception and Family Planning (when available)	Detailed contraceptive supply management, fertility awareness education, population implications
Doc #100 — Harakeke Fiber Processing	Harakeke processing for wound dressings and other medical textile applications
Doc #74 — Pastoral Farming Under Nuclear Winter	Food security context — maternal nutrition depends on food availability
Doc #157 — Trade Training	Includes health workforce training within broader recovery workforce development

---

APPENDIX A: BIRTH KIT FOR COMMUNITY BIRTH ATTENDANTS

A minimum community birth kit, designed for production and assembly using locally available materials once imported supplies deplete:

Item	Imported or local	Notes
Clean towels / cloth wraps	Local (wool, cotton, harakeke fiber)	For drying and warming newborn. Washable and reusable.
Cord ties / clamps	Local (sterilised string, woven cord)	Sterile cord tie; two required per birth.
Scissors or blade for cord cutting	Local (steel — reusable, sterilised)	Maintained and sharpened at regional hubs.
Bulb syringe for neonatal suction	Imported (while stocks last)	Improvisation from soft rubber possible but difficult.
Pinard horn or fetoscope	Local (wooden Pinard horn — turnable from native timber)	For fetal heart rate monitoring. No batteries required.
Blood pressure cuff and stethoscope	Imported (reusable — long-lasting)	Aneroid sphygmomanometers require periodic calibration.
Urine dipsticks (protein, glucose)	Imported (while stocks last)	No local substitute. Clinical assessment (oedema, symptoms) substitutes imperfectly for pre-eclampsia screening.
Sterile gloves	Imported initially; later laundered/resterilised latex	Resterilisation degrades integrity (Doc #117). Bare-hand delivery with antiseptic hand preparation is the historical alternative.
Oxytocin or misoprostol	Imported (while stocks last)	For AMTSL. When exhausted, manual AMTSL techniques.
Suture material and needle holder	Catgut or silk (local production — Doc #117)	For perineal repair.
Antiseptic solution	Local (ethanol-based, iodine tincture)	For hand preparation and wound cleaning.
Record book	Local (paper — Doc #5, Doc #29)	For documenting birth, maternal and neonatal observations.
Torch / light source	Battery or candle	For visual assessment in home settings without electric lighting.

---

---

1. Stats NZ, “Births and deaths: Year ended December 2023 (provisional).” https://www.stats.govt.nz/information-releases/births-and... — NZ recorded approximately 57,000–62,000 live births per year in recent years. The figure fluctuates; 60,000 is used as a round working estimate.↩︎

2. Ministry of Health / Te Whatu Ora. “Report on Maternity” series (annual). https://www.health.govt.nz/publication/report-maternity — The most recent available data (typically 1–2 years lag) shows approximately 94% LMC registration rate and approximately 92% of LMC registrations with midwife LMCs. These proportions have been stable for several years.↩︎

3. Sandall J, Soltani H, Gates S, Shennan A, Devane D. “Midwife-led continuity models versus other models of care for childbearing women.” Cochrane Database of Systematic Reviews, 2016, Issue 4. This Cochrane review found that women who received midwife-led continuity of care were less likely to experience interventions and more likely to be satisfied with their care, with no difference in adverse outcomes.↩︎

4. Perinatal and Maternal Mortality Review Committee (PMMRC). Annual reports. https://www.hqsc.govt.nz/our-work/mrc/pmmrc/ — PPH is consistently reported as the leading cause of severe acute maternal morbidity in NZ. The rate of PPH >1,000 mL is approximately 3–5% of births in NZ.↩︎

5. PMMRC annual reports. NZ’s maternal mortality ratio has fluctuated between approximately 8 and 20 per 100,000 births in recent reporting periods, depending on the definition used (direct maternal deaths vs. all pregnancy-related deaths) and the reporting year. The commonly cited figure of approximately 10–15 per 100,000 is a reasonable central estimate. The projected increase to 50–100 per 100,000 under isolation is an estimate based on historical maternal mortality in settings with skilled attendance but limited access to emergency obstetric care and uterotonics — see WHO maternal mortality estimates for lower-middle-income countries.↩︎

6. Ministry of Health / Te Whatu Ora. “Report on Maternity” — NZ’s caesarean section rate was approximately 27–28% in recent years. This includes both emergency and elective (planned) caesareans. The rate has increased gradually over recent decades and is consistent with trends in other high-income countries.↩︎

7. WHO Statement on Caesarean Section Rates, 2015. “Based on a systematic review, the WHO concludes that at the population level, caesarean section rates higher than 10% are not associated with reductions in maternal and newborn mortality rates.” The 5% lower bound is based on Molina G, et al., “Relationship between cesarean delivery rate and maternal and neonatal mortality,” JAMA 2015;314(21):2263–2270, which found that increasing C-section rates up to approximately 19% were associated with decreased mortality at the country level, with most benefit occurring below 10%.↩︎

8. PMMRC annual reports and Stats NZ. NZ neonatal mortality rate (deaths <28 days per 1,000 live births) has been approximately 2.7–3.2 in recent years. This is consistent with rates in comparable high-income countries.↩︎

9. Midwifery Council of New Zealand (MCNZ). Annual workforce survey data. https://www.midwiferycouncil.health.nz/ — The number of midwives holding Annual Practising Certificates has been approximately 3,200–3,400 in recent years. Not all APC holders are in active clinical practice; some are in education, management, or non-practising roles.↩︎

10. WHO recommendations for the prevention and treatment of postpartum haemorrhage, 2012 (updated 2018). Misoprostol 600 mcg oral or sublingual is recommended for PPH prevention where oxytocin is not available. WHO Model List of Essential Medicines includes misoprostol for this indication.↩︎

11. Midwifery Council of New Zealand (MCNZ). Annual workforce survey data. https://www.midwiferycouncil.health.nz/ — The number of midwives holding Annual Practising Certificates has been approximately 3,200–3,400 in recent years. Not all APC holders are in active clinical practice; some are in education, management, or non-practising roles.↩︎

12. Medical Council of New Zealand. “The New Zealand Medical Workforce” — annual workforce survey. The number of vocationally registered obstetrician-gynaecologists in NZ is approximately 200–250. The exact number depends on the reporting year and whether provisionally registered or non-practising registrants are included.↩︎

13. WHO, UNICEF, UNFPA, World Bank Group, and the United Nations Population Division. “Trends in Maternal Mortality: 2000 to 2020.” The global maternal mortality ratio was approximately 223 per 100,000 in 2020. Countries without skilled birth attendance and emergency obstetric care historically experienced rates of 500–1,500 per 100,000. The comparison to 50–100 per 100,000 assumes NZ retains skilled attendance (midwives) but loses pharmaceutical and some surgical capability.↩︎

14. Ministry of Health / Te Whatu Ora. “Report on Maternity” series (annual). https://www.health.govt.nz/publication/report-maternity — The most recent available data (typically 1–2 years lag) shows approximately 94% LMC registration rate and approximately 92% of LMC registrations with midwife LMCs. These proportions have been stable for several years.↩︎

15. Guilliland K, Pairman S. “The Midwifery Partnership: A Model for Practice.” Monograph Series 95/1, Victoria University of Wellington, 1995. Also: Nurses Amendment Act 1990, which restored autonomy to NZ midwives and enabled the development of the LMC model.↩︎

16. Ministry of Health / Te Whatu Ora. “Report on Maternity” series (annual). https://www.health.govt.nz/publication/report-maternity — The most recent available data (typically 1–2 years lag) shows approximately 94% LMC registration rate and approximately 92% of LMC registrations with midwife LMCs. These proportions have been stable for several years.↩︎

17. Ministry of Health / Te Whatu Ora. “Report on Maternity.” Birth setting data shows the distribution across tertiary/secondary hospitals, primary birthing units, and home births. The approximate percentages cited reflect recent years’ data.↩︎

18. Midwifery Council of New Zealand (MCNZ). Annual workforce survey data. https://www.midwiferycouncil.health.nz/ — The number of midwives holding Annual Practising Certificates has been approximately 3,200–3,400 in recent years. Not all APC holders are in active clinical practice; some are in education, management, or non-practising roles.↩︎

19. Midwifery Council of New Zealand. “Midwifery Education” and “Pathways to Registration.” https://www.midwiferycouncil.health.nz/ — The Bachelor of Midwifery is a four-year undergraduate degree offered at multiple institutions. The curriculum includes substantial clinical placement requirements.↩︎

20. Ministry of Health / Te Whatu Ora. “Maternity Services — Consumer Survey” and workforce planning documents. Geographic maldistribution of the midwifery workforce is a long-standing concern, with rural areas and some regions (East Cape, Northland, West Coast) experiencing shortages. Māori women are more likely to register late or not at all with an LMC.↩︎

21. Ministry of Health / Te Whatu Ora. “Maternity Services — Consumer Survey” and workforce planning documents. Geographic maldistribution of the midwifery workforce is a long-standing concern, with rural areas and some regions (East Cape, Northland, West Coast) experiencing shortages. Māori women are more likely to register late or not at all with an LMC.↩︎

22. Medical Council of New Zealand. “The New Zealand Medical Workforce” — annual workforce survey. The number of vocationally registered obstetrician-gynaecologists in NZ is approximately 200–250. The exact number depends on the reporting year and whether provisionally registered or non-practising registrants are included.↩︎

23. Kenney CM. “Midwives, women and their families: a Māori gaze: towards partnerships for maternity care in Aotearoa New Zealand.” AlterNative: An International Journal of Indigenous Peoples 2011;7(2):123–137.↩︎

24. Gupta JK, Sood A, Hofmeyr GJ, Vogel JP. “Position in the second stage of labour for women without epidural anaesthesia.” Cochrane Database of Systematic Reviews, 2017, Issue 5. Upright positions are associated with shorter second stage, fewer episiotomies, and fewer instrumental deliveries.↩︎

25. Bohren MA, Hofmeyr GJ, Sakala C, Fukuzawa RK, Cuthbert A. “Continuous support for women during childbirth.” Cochrane Database of Systematic Reviews, 2017, Issue 7. Continuous labour support reduces caesarean rates, instrumental delivery rates, and improves maternal satisfaction.↩︎

26. Birthplace in England Collaborative Group. “Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study.” BMJ 2011;343:d7400. This large study found that for multiparous low-risk women, planned home birth and birth centre birth had equivalent or better outcomes compared with hospital birth. For nulliparous women, home birth had slightly higher rates of adverse perinatal outcomes, though absolute risks remained low.↩︎

27. Based on NZ Referral Guidelines for consultation with obstetric and related medical services (Section 88, Primary Maternity Services Notice). These guidelines specify clinical indications for obstetric consultation and transfer of care.↩︎

28. RCOG Green-top Guideline No. 45: Birth After Previous Caesarean Birth, 2015 (updated). VBAC success rates of 72–76% reported in large studies. Uterine rupture risk approximately 0.5% (1 in 200) for women with one prior lower-segment caesarean.↩︎

29. Oxytocin (Syntocinon) — Medsafe Datasheet, NZ. https://www.medsafe.govt.nz/profs/datasheet/s/Syntocinoni... — Synthetic oxytocin for induction/augmentation of labour (IV infusion) and prevention/treatment of PPH (IM injection, 5–10 IU).↩︎

30. Begley CM, Gyte GML, Devane D, McGuire W, Weeks A, Biesty LM. “Active versus expectant management for women in the third stage of labour.” Cochrane Database of Systematic Reviews, 2019, Issue 2. Active management (oxytocin + controlled cord traction) reduces the risk of PPH >1,000 mL by approximately 50–60% compared with expectant management.↩︎

31. Estimate. NZ’s oxytocin consumption is not publicly reported at aggregate level. The estimate of 60,000–80,000 ampoules per year is based on approximately 60,000 births, AMTSL for most births (5–10 IU per birth), plus additional use for induction, augmentation, and treatment of PPH. This figure requires verification from Te Whatu Ora/PHARMAC procurement data.↩︎

32. Du Vigneaud V, Ressler C, Trippett S. “The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin.” Journal of Biological Chemistry 1953;205(2):949–957. Oxytocin structure: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ with a 1–6 disulfide bridge.↩︎

33. WHO recommendations for the prevention and treatment of postpartum haemorrhage, 2012 (updated 2018). Misoprostol 600 mcg oral or sublingual is recommended for PPH prevention where oxytocin is not available. WHO Model List of Essential Medicines includes misoprostol for this indication.↩︎

34. Tunçalp Ö, Hofmeyr GJ, Gülmezoglu AM. “Prostaglandins for preventing postpartum haemorrhage.” Cochrane Database of Systematic Reviews, 2012, Issue 8. Misoprostol is less effective than injectable oxytocin but more effective than placebo for PPH prevention.↩︎

35. De Costa C. “St Anthony’s fire and living ligatures: a short history of ergometrine.” Lancet 2002;359(9319):1768–1770. Ergot alkaloids have been used to control postpartum bleeding since the 16th century.↩︎

36. Altman D, Carroli G, Duley L, et al. “Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.” Lancet 2002;359(9321):1877–1890. Magnesium sulfate halved the risk of eclampsia in women with pre-eclampsia.↩︎

37. ACOG Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology, 2020;135(6):e237–e260. Pre-eclampsia affects approximately 2–8% of pregnancies worldwide.↩︎

38. NZ Guidelines Group / Ministry of Health. “NZ Consensus Statement on Group B Streptococcus.” GBS colonisation affects approximately 20–25% of pregnant women. Intrapartum antibiotic prophylaxis (IAP) with penicillin reduces early-onset GBS disease from approximately 1–3 per 1,000 to <0.5 per 1,000 live births.↩︎

39. Schrag SJ, et al. “Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.” NEJM 2000;342:15–20. Case fatality rate for early-onset GBS sepsis in term neonates approximately 4–6%; higher in premature infants.↩︎

40. Smaill FM, Grivell RM. “Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section.” Cochrane Database of Systematic Reviews, 2014, Issue 10. Prophylactic antibiotics reduce wound infection after caesarean section by approximately 60–70%.↩︎

41. The historical effectiveness of early (impure) penicillin in reducing surgical and wound infection mortality is well documented. Florey HW, et al. “Penicillin as a chemotherapeutic agent.” Lancet 1940;236(6104):226–228. Early clinical use of crude penicillin reduced mortality from bacteraemia and wound infection dramatically — from approximately 80–90% to 20–40% for serious staphylococcal infections, despite inconsistent dosing and purity. The dosing consistency estimate (50–80% of target) reflects the challenges of early fermentation-based production without modern analytical quality control; see Hobby GL, “Penicillin: Meeting the Challenge,” Yale University Press, 1985.↩︎

42. RCOG Green-top Guideline No. 29: The Management of Third- and Fourth-Degree Perineal Tears, 2015. First/second degree tears are common (40–60% of vaginal births depending on parity and definition). Third/fourth degree (involving the anal sphincter) occur in approximately 3–5%.↩︎

43. Butts CA, et al. “Bioactive properties of selected New Zealand native plants: kawakawa (Macropiper excelsum).” NZ plant-based research. The myristicin and other compounds in kawakawa have demonstrated anti-inflammatory activity in laboratory studies.↩︎

44. Molan PC. “The evidence supporting the use of honey as a wound dressing.” International Journal of Lower Extremity Wounds 2006;5(1):40–54. Mānuka honey (from Leptospermum scoparium) has particularly high antibacterial activity due to methylglyoxal content. Medihoney and similar products are approved for wound care in NZ and internationally.↩︎

45. Riley M. Māori Healing and Herbal: New Zealand Ethnobotanical Sourcebook. Viking Sevenseas NZ Ltd, 1994. A comprehensive reference on rongoā Māori plant medicines, though it should be supplemented with direct practitioner knowledge.↩︎

46. Brook FJ, et al. Research on antimicrobial properties of Phormium (harakeke) fiber gel. Published in NZ Journal of Botany and related journals. The mucilaginous gel from harakeke leaf bases has demonstrated antibacterial properties against common wound pathogens.↩︎

47. Puckett RM, Offringa M. “Prophylactic vitamin K for vitamin K deficiency bleeding in neonates.” Cochrane Database of Systematic Reviews, 2000, Issue 4. Intramuscular vitamin K is more effective than oral vitamin K for preventing late-onset VKDB, though multiple oral doses provide partial protection.↩︎

48. Approximately 15% of European-descent populations are Rh-negative. The proportion is lower in Māori and Pacific populations. NZ Rh-negative prevalence is estimated at approximately 15% overall given the European-majority population. Without anti-D prophylaxis, approximately 16% of Rh-negative women will develop antibodies after an Rh-positive pregnancy.↩︎

49. Ultrasound coupling gels are typically water-based polymer gels. Commercial formulations use carbomer (polyacrylic acid) or similar synthetic polymers. Functional substitutes can be produced from natural hydrocolloids including agar and carboxymethylcellulose (CMC). CMC is produced from wood pulp cellulose by reaction with chloroacetic acid in the presence of sodium hydroxide — see standard industrial cellulose chemistry references. Acoustic coupling performance of natural-gum substitutes has not been systematically compared with commercial ultrasound gel in published literature; the performance gap claim is based on general acoustic impedance matching principles.↩︎

50. Whitworth M, Bricker L, Mullan C. “Ultrasound for fetal assessment in early pregnancy.” Cochrane Database of Systematic Reviews, 2015, Issue 7. Routine ultrasound screening in early pregnancy detects multiple pregnancy, placenta praevia, and major fetal anomalies that affect birth planning.↩︎

51. Estimate based on general medical equipment longevity data and biomedical engineering experience. Ultrasound probe lifespan is typically 5–8 years under heavy use, longer with careful handling. Machine electronics (motherboards, displays, power supplies) typically last 10–15 years. Exact lifespan depends on usage intensity, maintenance quality, and environmental conditions.↩︎

52. Ministry of Health / Te Whatu Ora. “Report on Maternity” — NZ’s caesarean section rate was approximately 27–28% in recent years. This includes both emergency and elective (planned) caesareans. The rate has increased gradually over recent decades and is consistent with trends in other high-income countries.↩︎

53. The categorisation of caesarean indications is approximate and based on general obstetric literature and NZ clinical data from “Report on Maternity.” The proportions are estimates; precise breakdown varies by institution and year.↩︎

54. WHO Statement on Caesarean Section Rates, 2015. “Based on a systematic review, the WHO concludes that at the population level, caesarean section rates higher than 10% are not associated with reductions in maternal and newborn mortality rates.” The 5% lower bound is based on Molina G, et al., “Relationship between cesarean delivery rate and maternal and neonatal mortality,” JAMA 2015;314(21):2263–2270, which found that increasing C-section rates up to approximately 19% were associated with decreased mortality at the country level, with most benefit occurring below 10%.↩︎

55. RCOG Green-top Guideline No. 45: Birth After Previous Caesarean Birth, 2015 (updated). VBAC success rates of 72–76% reported in large studies. Uterine rupture risk approximately 0.5% (1 in 200) for women with one prior lower-segment caesarean.↩︎

56. Goffinet F, et al. “Is planned vaginal delivery for breech presentation at term still an option? Results of an observational prospective survey in France and Belgium.” American Journal of Obstetrics & Gynecology 2006;194(4):1002–1011. Also: Kotaska A. “Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery.” BMJ 2004;329:1039–1042. Breech vaginal birth is safe in selected cases with experienced practitioners, though the skill has been lost in many training programmes following the Term Breech Trial (Hannah et al., Lancet 2000).↩︎

57. Based on analysis of per-case consumable requirements in Doc #117 and anaesthetic requirements. Spinal anaesthesia for caesarean section requires approximately 2–3 mL of bupivacaine (0.5%) or lignocaine per case, a spinal needle (reusable if sterilised), and antiseptic for skin preparation.↩︎

58. Perinatal and Maternal Mortality Review Committee (PMMRC). Annual reports. https://www.hqsc.govt.nz/our-work/mrc/pmmrc/ — PPH is consistently reported as the leading cause of severe acute maternal morbidity in NZ. The rate of PPH >1,000 mL is approximately 3–5% of births in NZ.↩︎

59. Begley CM, Gyte GML, Devane D, McGuire W, Weeks A, Biesty LM. “Active versus expectant management for women in the third stage of labour.” Cochrane Database of Systematic Reviews, 2019, Issue 2. Active management (oxytocin + controlled cord traction) reduces the risk of PPH >1,000 mL by approximately 50–60% compared with expectant management.↩︎

60. WHO. “WHO recommendations for the prevention and treatment of postpartum haemorrhage.” 2012 (updated 2018). These guidelines include recommendations for uterine massage, bimanual compression, and uterine balloon tamponade when pharmacological treatment is unavailable or insufficient.↩︎

61. Georgiou C. “Balloon tamponade in the management of postpartum haemorrhage: a review.” BJOG 2009;116(6):748–757. Condom catheter tamponade is a well-validated technique for resource-limited settings — a condom tied over a Foley catheter and inflated with saline (300–500 mL) provides intrauterine tamponade.↩︎

62. Al-Snafi AE. “The chemical constituents and pharmacological effects of Capsella bursa-pastoris — A review.” International Journal of Pharmacology and Toxicology 2015;5(2):76–81. Reports on traditional use and some pharmacological evidence for uterotonic properties. Clinical trial evidence for PPH prevention is absent.↩︎

63. PMMRC annual reports. NZ’s maternal mortality ratio has fluctuated between approximately 8 and 20 per 100,000 births in recent reporting periods, depending on the definition used (direct maternal deaths vs. all pregnancy-related deaths) and the reporting year. The commonly cited figure of approximately 10–15 per 100,000 is a reasonable central estimate. The projected increase to 50–100 per 100,000 under isolation is an estimate based on historical maternal mortality in settings with skilled attendance but limited access to emergency obstetric care and uterotonics — see WHO maternal mortality estimates for lower-middle-income countries.↩︎

64. WHO, UNICEF, UNFPA, World Bank Group, and the United Nations Population Division. “Trends in Maternal Mortality: 2000 to 2020.” The global maternal mortality ratio was approximately 223 per 100,000 in 2020. Countries without skilled birth attendance and emergency obstetric care historically experienced rates of 500–1,500 per 100,000. The comparison to 50–100 per 100,000 assumes NZ retains skilled attendance (midwives) but loses pharmaceutical and some surgical capability.↩︎

65. PMMRC annual reports and Stats NZ. NZ neonatal mortality rate (deaths <28 days per 1,000 live births) has been approximately 2.7–3.2 in recent years. This is consistent with rates in comparable high-income countries.↩︎

66. Estimated from NZ NICU admission data. The Australasian neonatal network (ANZNN) reports on neonatal admissions across NZ and Australia. Approximately 8–10% of NZ newborns require some level of neonatal unit admission; approximately 1.5–2% require intensive care (Level 3).↩︎

67. Horbar JD, et al. “Trends in mortality and morbidity for very low birth weight infants, 1991–1999.” Pediatrics 2002;110(1 Pt 1):143–151. Before surfactant (available from the early 1990s), mortality for infants <1,000 g was approximately 50%. Surfactant therapy reduced mortality by approximately 30–40% for very premature infants. Without surfactant, the pre-surfactant mortality rates apply.↩︎

68. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. “Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.” Pediatrics 2004;114(1):297–316. Phototherapy for neonatal jaundice uses blue light in the 460–490 nm wavelength range, which is absorbed by bilirubin and converts it to water-soluble isomers that can be excreted. This is visible blue light, not ultraviolet radiation.↩︎

69. Conde-Agudelo A, Díaz-Rossello JL. “Kangaroo mother care to reduce morbidity and mortality in low birthweight infants.” Cochrane Database of Systematic Reviews, 2016, Issue 8. KMC reduces mortality, sepsis, hypothermia, and hospital stay in low birth weight infants compared with conventional incubator care in resource-limited settings.↩︎

70. Horbar JD, et al. “Trends in mortality and morbidity for very low birth weight infants, 1991–1999.” Pediatrics 2002;110(1 Pt 1):143–151. Before surfactant (available from the early 1990s), mortality for infants <1,000 g was approximately 50%. Surfactant therapy reduced mortality by approximately 30–40% for very premature infants. Without surfactant, the pre-surfactant mortality rates apply.↩︎

71. Horbar JD, et al. “Trends in mortality and morbidity for very low birth weight infants, 1991–1999.” Pediatrics 2002;110(1 Pt 1):143–151. Before surfactant (available from the early 1990s), mortality for infants <1,000 g was approximately 50%. Surfactant therapy reduced mortality by approximately 30–40% for very premature infants. Without surfactant, the pre-surfactant mortality rates apply.↩︎

72. Conde-Agudelo A, Díaz-Rossello JL. “Kangaroo mother care to reduce morbidity and mortality in low birthweight infants.” Cochrane Database of Systematic Reviews, 2016, Issue 8. KMC reduces mortality, sepsis, hypothermia, and hospital stay in low birth weight infants compared with conventional incubator care in resource-limited settings.↩︎

73. WHO. “Strengthening quality midwifery education for Universal Health Coverage 2030.” WHO, 2019. Also: “Making pregnancy safer: the critical role of the skilled attendant.” WHO/ICM/FIGO joint statement, 2004. The WHO endorses skilled birth attendance as the primary strategy for reducing maternal mortality, with community-level training programmes as a component of comprehensive maternity systems.↩︎

74. Goffinet F, et al. “Is planned vaginal delivery for breech presentation at term still an option? Results of an observational prospective survey in France and Belgium.” American Journal of Obstetrics & Gynecology 2006;194(4):1002–1011. Also: Kotaska A. “Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery.” BMJ 2004;329:1039–1042. Breech vaginal birth is safe in selected cases with experienced practitioners, though the skill has been lost in many training programmes following the Term Breech Trial (Hannah et al., Lancet 2000).↩︎

75. Ministry of Health / Te Whatu Ora. “Report on Maternity” — operative vaginal delivery data shows vacuum extraction is now far more common than forceps delivery in NZ. This trend mirrors international patterns. Obstetrician training in forceps delivery has declined as vacuum extraction has become the preferred instrument. RANZCOG training curriculum still includes forceps, but clinical exposure opportunities have diminished.↩︎

76. Björklund K. “Minimally invasive surgery for obstructed labour: a review of symphysiotomy during the twentieth century (including 5,000 cases).” BJOG 2002;109(3):236–248. Symphysiotomy was widely used in settings without access to caesarean section and has a lower complication rate than commonly perceived, particularly when performed by trained practitioners.↩︎

77. PHARMAC. Pharmaceutical schedule and usage data. Contraceptive methods funded and distributed in NZ include combined oral contraceptives, progestogen-only pills, medroxyprogesterone acetate injection (Depo-Provera), levonorgestrel subdermal implant (Jadelle), and copper and hormonal IUDs. All are imported products.↩︎

78. Trussell J. “Contraceptive failure in the United States.” Contraception 2011;83(5):397–404. Typical-use failure rates for fertility awareness-based methods range from approximately 12–24% per year depending on the specific method and adherence. Perfect-use failure rates are much lower (1–5%) but require consistent, correct application.↩︎